Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results

Structure Therapeutics' GLP-1 pill cut patients’ body weight by a placebo-adjusted average of 11.3% at around eight and a half months. This is competitive with both Eli Lilly’s orforglipron and Novo Nordisk’s oral formulation of ...